Lexaria Bioscience Corp. (LEXX)
$3.66+$0.56 (+18.26%) Latest session
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
https://www.lexariabioscience.comSEC filings for LEXX on EDGAR
No Form 4 activity for LEXX in the last 90 days.
10 Form 4 filings on record, the earliest from Dec 3, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christopher Bunka - Director | Gift | common shares | 100,000 | $0.00 | - | |
| Christopher Bunka - Director | Open-market purchase | common shares | 15,600 | $13.82 | $14K | |
| Christopher Bunka - Director | Open-market purchase | common shares | 11,900 | $13.70 | $11K | |
| Richard Christopher - Officer | Open-market purchase | common shares | 15,000 | $13.64 | $14K | |
| William Edward McKechnie - Director | Open-market purchase | common shares | 5,000 | $13.59 | $5K | |
| John Martin Docherty - Officer | Open-market purchase | common shares | 5,376 | $13.92 | $5K | |
| Vanessa Carle - Officer | Open-market purchase | common shares | 750 | $13.65 | $683 | |
| Albert L. Reese Jr. - Director | Grant or award | Stock Options | 11,000 | $0.00 | - | |
| Richard Christopher - Officer | Grant or award | Stock Options | 150,000 | $0.00 | - | |
| Christopher Bunka - Director | Grant or award | Stock Options | 11,000 | $0.00 | - | |
| Richard Christopher - Officer | Open-market purchase | common shares | 22,828 | $33.65 | $51K | |
| Richard Christopher - Officer | Open-market purchase | common shares | 27,172 | $37.08 | $67K |
Lexaria Bioscience Corp. (LEXX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-03-18. The full record for LEXX runs to 10 Form 4 filings, the earliest from 2024-12-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of LEXX were filed in the last 90 days. 8 purchases are on record for this company.
No insider sales of LEXX were filed in the last 90 days.
This page tracks LEXX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add LEXX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
